AbCellera Biologics (ABCL) Total Non-Current Liabilities (2020 - 2025)
Historic Total Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $323.2 million.
- AbCellera Biologics' Total Non-Current Liabilities rose 3741.36% to $323.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.2 million, marking a year-over-year increase of 3741.36%. This contributed to the annual value of $227.9 million for FY2024, which is 511.8% up from last year.
- As of Q3 2025, AbCellera Biologics' Total Non-Current Liabilities stood at $323.2 million, which was up 3741.36% from $328.0 million recorded in Q2 2025.
- AbCellera Biologics' Total Non-Current Liabilities' 5-year high stood at $328.0 million during Q2 2025, with a 5-year trough of $83.0 million in Q1 2021.
- Its 5-year average for Total Non-Current Liabilities is $207.1 million, with a median of $216.8 million in 2023.
- Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 14065.53% in 2021, then soared by 344.58% in 2024.
- Over the past 5 years, AbCellera Biologics' Total Non-Current Liabilities (Quarter) stood at $172.2 million in 2021, then grew by 9.96% to $189.3 million in 2022, then rose by 14.5% to $216.8 million in 2023, then increased by 5.12% to $227.9 million in 2024, then soared by 41.82% to $323.2 million in 2025.
- Its Total Non-Current Liabilities was $323.2 million in Q3 2025, compared to $328.0 million in Q2 2025 and $245.8 million in Q1 2025.